ExpreS2ion Biotech Holding AB (FRA:5JD0) Cyclically Adjusted FCF per Share: €-1.52 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5JD0 ExpreS2ion Biotech Holding AB FRA:5JD0
43 GF Score
Price €0.10
GF Value €0.34
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Cyclically Adjusted FCF per Share?

ExpreS2ion Biotech Holding AB FRA:5JD0 +2.26% 43 Cyclically Adjusted FCF per Share is €-1.52 as of Mar. 2026. GuruFocus rates FRA:5JD0 with a GF Score™ of 43/100 and a GF Value™ of €0.34 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ExpreS2ion Biotech Holding AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.019. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.52 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-19), ExpreS2ion Biotech Holding AB's current stock price is €0.0994. ExpreS2ion Biotech Holding AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-1.52. ExpreS2ion Biotech Holding AB's Cyclically Adjusted Price-to-FCF of today is .


ExpreS2ion Biotech Holding AB  (FRA:5JD0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ExpreS2ion Biotech Holding AB Cyclically Adjusted FCF per Share Related Terms


ExpreS2ion Biotech Holding AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB Cyclically Adjusted FCF per Share Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.70

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.77 -1.79 -1.70 -1.52

FRA:5JD0 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:5JD0
43GF Score
ExpreS2ion Biotech Holding AB FRA:5JD0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ExpreS2ion Biotech Holding AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.019/133.5600*133.5600
=-0.019

Current CPI (Mar. 2026) = 133.5600.

ExpreS2ion Biotech Holding AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -1.404 100.751 -1.861
201609 1.391 101.138 1.837
201612 -0.277 102.022 -0.363
201703 -0.488 102.022 -0.639
201706 -0.117 102.752 -0.152
201709 -0.116 103.279 -0.150
201712 -0.265 103.793 -0.341
201803 -0.193 103.962 -0.248
201806 -0.479 104.875 -0.610
201809 -0.188 105.679 -0.238
201812 -0.257 105.912 -0.324
201903 -0.271 105.886 -0.342
201906 -0.405 106.742 -0.507
201909 -0.176 107.214 -0.219
201912 -0.126 107.766 -0.156
202003 -0.567 106.563 -0.711
202006 0.237 107.498 0.294
202009 -0.300 107.635 -0.372
202012 -0.390 108.296 -0.481
202103 -0.967 108.360 -1.192
202106 -0.372 108.928 -0.456
202109 -0.273 110.338 -0.330
202112 -0.145 112.486 -0.172
202203 -0.562 114.825 -0.654
202206 -0.734 118.384 -0.828
202209 -0.707 122.296 -0.772
202212 -1.088 126.365 -1.150
202303 -1.119 127.042 -1.176
202306 -0.887 129.407 -0.915
202309 -0.289 130.224 -0.296
202312 -0.346 131.912 -0.350
202403 0.015 132.205 0.015
202406 -0.137 132.716 -0.138
202409 -0.142 132.304 -0.143
202412 -0.055 132.987 -0.055
202503 -0.186 132.825 -0.187
202506 -0.098 133.699 -0.098
202509 -0.094 133.480 -0.094
202512 0.006 133.390 0.006
202603 -0.019 133.560 -0.019

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.52 mean?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a Cyclically Adjusted FCF per Share of €-1.52 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Cyclically Adjusted FCF per Share too high?
ExpreS2ion Biotech Holding AB's current Cyclically Adjusted FCF per Share is €-1.52. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Cyclically Adjusted FCF per Share of €-1.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Cyclically Adjusted FCF per Share is €-1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (FRA:5JD0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.34, compared to a current price of €0.10 — trading 70.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1.52. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current Cyclically Adjusted FCF per Share is €-1.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of €0.10 is trading 70.8% below its estimated GF Value™ of €0.34. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for FRA:5JD0:

  • Cyclically Adjusted FCF per Share: €-1.52
  • GF Value™: €0.34 vs. price of €0.10 (70.8% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ExpreS2ion Biotech Holding AB Business Description

Other Exchanges EXPRS2:Sweden
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for FRA:5JD0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.34
GF Value